-
Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™
30 Jan 2025 12:30 GMT
… (858) 717-2310
david.schull@russopartnersllc.com
-
Triumvira Immunologics Presents Updated Clinical Data at the 2025 ASCO Gastrointestinal Cancers Symposium
28 Jan 2025 12:33 GMT
… -942-5604
ignacio.guerrero-ros@russopartnersllc.com
View original content to download …
-
NervGen Engages Russo Partners LLC to Provide Public Relations Services
25 Apr 2024 23:32 GMT
… . For more information, visit www.russopartnersllc.com or follow Russo Partners on … Partners
david.schull@russopartnersllc.com
ignacio.guerrero-ros@russopartnersllc.com
858.717.2310
646 …
-
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies
23 Jan 2025 13:03 GMT
…
(858) 717-2310
david.schull@russopartnersllc.com
-
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
21 Jan 2025 13:19 GMT
…
(858) 717-2310
david.schull@russopartnersllc.com
-
iBio Announces New Investments from Board Members and Officers
13 Jan 2025 12:00 GMT
… , LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or …
-
Diakonos Oncology to Present at Biotech Showcase 2025
11 Jan 2025 13:33 GMT
…
858-717-2310
david.schull@russopartnersllc.com
View original content:https:…
-
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
08 Jan 2025 17:30 GMT
…
(858) 717-2310
david.schull@russopartnersllc.com
-
Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287
08 Jan 2025 13:00 GMT
… and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(760) 846-9256
-
iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
07 Jan 2025 12:00 GMT
… , LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or …